There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 15 years ago. Many of the new classes of agents, however, are predicted to work in only small subpopulations of patients, target unconventional aspects of tumour development and interact with other agents in an unpredictable manner. How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?
|Original language||English (US)|
|Number of pages||7|
|Journal||Nature Reviews Cancer|
|State||Published - Apr 2003|
ASJC Scopus subject areas
- Cancer Research